Founded by three cardiologists and a data scientist in 2016 in Marseille, Volta Medical is a HealthTech company developing artificial intelligence (AI) software solutions to assist cardiac electrophysiologists in the operating room. Volta’s overarching goal is to drastically improve cardiac arrythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection. Its first product, VX1, assists cardiologists for the real-time identification of specific abnormal electrograms, known as dispersed electrograms.
In September 2020, Volta attained FDA approval for its VX1 system, a first for an AI based software in interventional electrophysiology. Gilde invested in Volta in 2020 to enable the company to establish its revolutionary FDA-cleared and CE marked VX1 AI software solution as a new standard of care, pursue further R&D activities and start to roll out commercial activities across the US and Europe.